Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.14% $14.71
America/New_York / 24 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 213.76 mill |
EPS: | -0.0800 |
P/E: | -183.87 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 14.53 mill |
Avg Daily Volume: | 0.130 mill |
RATING 2024-04-23 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -183.87 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-31.28x |
Company: PE -183.87 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.419 (-97.15%) $-14.29 |
Date: 2024-04-24 |
Expected Trading Range (DAY) |
---|
$ 14.59 - 14.83 ( +/- 0.81%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-28 | Andersen Eric | Buy | 857 | Common Stock |
2023-12-26 | Andersen Eric | Buy | 48 693 | Common Stock |
2023-12-07 | Andersen Eric | Buy | 76 384 | Common Stock |
2023-12-07 | Andersen Eric | Buy | 24 666 | Common Stock |
2023-11-17 | Andersen Eric | Buy | 235 | Common Stock |
INSIDER POWER |
---|
99.78 |
Last 100 transactions |
Buy: 1 159 920 | Sell: 7 000 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $14.71 (-0.14% ) |
Volume | 0.106 mill |
Avg. Vol. | 0.130 mill |
% of Avg. Vol | 81.37 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.